HASBROUCK HEIGHTS, N.J., March 13, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2008. Nymox reported a net loss of $4,590,345, or $0.15 per share for the year ended December 31, 2008, compared to $5,290,431, or $0.18 per share for the same period in 2007. The decrease in net losses is attributable to a reduction in expenditures relating to clinical trials in the period. The net loss in 2008 includes Stock Based Compensation charges of $925,220 and amortization and write-down of costs totaling $808,581. Product sales amounted to $426,675 for the year ended December 31, 2008, compared to $412,923 for the same period in 2007. The weighted average number of common shares at the year ended December 31, 2008 was 29,749,000, compared to 29,005,342 at December 31, 2007.
